Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANOFI INDIA Dec-18 |
MYLAN Dec-18 |
SANOFI INDIA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 6,840 | 3,481 | - | |
Low | Rs | 4,630 | 1,916 | - | |
Sales per share (Unadj.) | Rs | 1,203.1 | 1,602.0 | - | |
Earnings per share (Unadj.) | Rs | 165.3 | 43.5 | - | |
Cash flow per share (Unadj.) | Rs | 209.9 | 343.5 | - | |
Dividends per share (Unadj.) | Rs | 84.00 | 0 | - | |
Dividend yield (eoy) | % | 1.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 963.6 | 1,733.0 | - | |
Shares outstanding (eoy) | m | 23.03 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.8 | 1.7 | 282.9% | |
Avg P/E ratio | x | 34.7 | 62.0 | 55.9% | |
P/CF ratio (eoy) | x | 27.3 | 7.9 | 347.8% | |
Price / Book Value ratio | x | 6.0 | 1.6 | 382.2% | |
Dividend payout | % | 50.8 | 0 | - | |
Avg Mkt Cap | Rs m | 132,078 | 1,388,567 | 9.5% | |
No. of employees | `000 | 3.3 | 35.0 | 9.4% | |
Total wages/salary | Rs m | 4,068 | 0 | - | |
Avg. sales/employee | Rs Th | 8,393.8 | 23,549.0 | 35.6% | |
Avg. wages/employee | Rs Th | 1,232.4 | 0 | - | |
Avg. net profit/employee | Rs Th | 1,153.0 | 639.5 | 180.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 27,708 | 824,215 | 3.4% | |
Other income | Rs m | 897 | 0 | - | |
Total revenues | Rs m | 28,605 | 824,215 | 3.5% | |
Gross profit | Rs m | 6,235 | 213,276 | 2.9% | |
Depreciation | Rs m | 1,027 | 154,325 | 0.7% | |
Interest | Rs m | 7 | 39,642 | 0.0% | |
Profit before tax | Rs m | 6,098 | 19,309 | 31.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,292 | -3,072 | -74.6% | |
Profit after tax | Rs m | 3,806 | 22,381 | 17.0% | |
Gross profit margin | % | 22.5 | 25.9 | 87.0% | |
Effective tax rate | % | 37.6 | -15.9 | -236.3% | |
Net profit margin | % | 13.7 | 2.7 | 505.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 15,922 | 460,241 | 3.5% | |
Current liabilities | Rs m | 6,235 | 335,566 | 1.9% | |
Net working cap to sales | % | 35.0 | 15.1 | 231.1% | |
Current ratio | x | 2.6 | 1.4 | 186.2% | |
Inventory Days | Days | 64 | 84 | 76.2% | |
Debtors Days | Days | 21 | 93 | 22.4% | |
Net fixed assets | Rs m | 7,539 | 159,884 | 4.7% | |
Share capital | Rs m | 230 | 439 | 52.4% | |
Net worth | Rs m | 22,192 | 891,650 | 2.5% | |
Long term debt | Rs m | 0 | 962,376 | 0.0% | |
Total assets | Rs m | 29,839 | 2,391,751 | 1.2% | |
Interest coverage | x | 872.1 | 1.5 | 58,647.8% | |
Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.3 | 269.5% | |
Return on assets | % | 12.8 | 2.6 | 492.8% | |
Return on equity | % | 17.2 | 2.5 | 683.3% | |
Return on capital | % | 27.5 | 3.2 | 865.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,739 | 171,272 | 2.2% | |
From Investments | Rs m | -731 | -88,529 | 0.8% | |
From Financial Activity | Rs m | -1,972 | -79,788 | 2.5% | |
Net Cashflow | Rs m | 1,036 | 1,419 | 73.0% |
Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare SANOFI INDIA With: DISHMAN PHARMA ALKEM LABORATORIES TTK HEALTHCARE CADILA HEALTHCARE GLENMARK PHARMA
Indian share markets continued their momentum and ended their day on a strong note today.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More